Blackrock Inc vs BioNano Genomics Inc — how do they compare? Blackrock Inc trades at $1,095.5 (market cap $158.94B), while BioNano Genomics Inc trades at $1.18 (market cap $13.20M). The key difference: Blackrock Inc is far larger — about 12040.9× BioNano Genomics Inc's market cap, and Blackrock Inc pays a 2.24% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BLK | BNGO | |
|---|---|---|
Market Cap | $158.94B | $13.20M |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $4.92 |
52-Week Low | $922.90 | $1.09 |
Enterprise Value | $160.76B | $15.81M |
Dividend Yield | 2.24% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Trailing returns across standard periods
Latest headlines on both assets
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →